Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

[1]  G. Hortobagyi,et al.  Trastuzumab-related cardiotoxicity among older patients with breast cancer. , 2013, Journal of Clinical Oncology.

[2]  H. D. de Koning,et al.  Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. , 2013, Journal of the National Cancer Institute.

[3]  M. Greuter,et al.  Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness , 2013, British Journal of Cancer.

[4]  E. Halpern,et al.  Cost‐effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers , 2013, Cancer.

[5]  Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers , 2013, BMC Cancer.

[6]  R. Warren,et al.  Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[7]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jeffrey Allen.  Economic/societal burden of metastatic breast cancer: a US perspective. , 2010, The American journal of managed care.

[9]  J. Lubitz,et al.  Long-term trends in Medicare payments in the last year of life. , 2010, Health services research.

[10]  A. Stewart,et al.  Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer , 2010, Cancer investigation.

[11]  Karla Kerlikowske,et al.  Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. , 2009, Journal of the National Cancer Institute.

[12]  G. Oster,et al.  Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. , 2009, Journal of the American College of Radiology : JACR.

[13]  C. Ahern,et al.  Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  C. Flowers,et al.  Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population , 2009, BMC health services research.

[15]  Nelia Afonso,et al.  Women at High Risk for Breast Cancer—What the Primary Care Provider Needs to Know , 2009, The Journal of the American Board of Family Medicine.

[16]  F. Siannis,et al.  Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. , 2008, The oncologist.

[17]  Odd O Aalen,et al.  Breast cancer tumor growth estimated through mammography screening data , 2008, Breast Cancer Research.

[18]  Angela Mariotto,et al.  Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.

[19]  R. Warren,et al.  BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials , 2007, Clinical Cancer Research.

[20]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[21]  R. Theriault,et al.  Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? , 2007, Breast Cancer Research and Treatment.

[22]  E. Feuer,et al.  Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. , 2006, Journal of the National Cancer Institute. Monographs.

[23]  Karla Kerlikowske,et al.  Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.

[24]  H. D. de Koning,et al.  Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer , 2006, Breast Cancer Research and Treatment.

[25]  C. Flowers,et al.  Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Bruce L Daniel,et al.  Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. , 2006, JAMA.

[27]  Brekelmans,et al.  Factors affecting sensitivity and specificity of screening mammography and MRI in women with a hereditary risk for breast cancer , 2006 .

[28]  G. Parmigiani,et al.  Optimization of Breast Cancer Screening Modalities , 2006 .

[29]  S. Plevritis,et al.  Cost-effectiveness of Screening BRCA 1 / 2 Mutation Carriers With Breast Magnetic Resonance Imaging , 2006 .

[30]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[31]  Giovanni Parmigiani,et al.  A Model-Based Comparison of Breast Cancer Screening Strategies: Mammograms and Clinical Breast Examinations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[32]  A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study , 1985, World Journal of Surgery.

[33]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[34]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[35]  C. Kuhl,et al.  Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial , 2003 .

[36]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[37]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[38]  W. P. Evans,et al.  American Cancer Society Guidelines for Breast Cancer Screening: Update 2003 , 2003, CA: a cancer journal for clinicians.

[39]  Eric R. Ziegel,et al.  Modeling in Medical Decision Making , 2002, Technometrics.

[40]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Legare,et al.  Adjuvant therapy in breast cancer. , 2002, Obstetrics and gynecology clinics of North America.

[42]  T J Ulahannan,et al.  Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .

[43]  M Zelen,et al.  Testing the Independence of Two Diagnostic Tests , 2001, Biometrics.

[44]  John M. Colford,et al.  Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, Second Edition , 2001 .

[45]  D. Buist,et al.  Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. , 2001, Journal of the National Cancer Institute.

[46]  K. Kerlikowske,et al.  Performance of Screening Mammography among Women with and without a First-Degree Relative with Breast Cancer , 2000, Annals of Internal Medicine.

[47]  Tammy O. Tengs,et al.  One thousand health-related quality-of-life estimates. , 2000, Medical care.

[48]  L. Tabár,et al.  Estimation of Sojourn Time in Chronic Disease Screening Without Data on Interval Cases , 2000, Biometrics.

[49]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[50]  L. Norton,et al.  Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[52]  Giovanni Parmigiani,et al.  On Optimal Screening Ages , 1993 .

[53]  W. Odling-Smee,et al.  Screening for Breast Cancer , 1985, The Lancet.